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Comparison of Chronic Wound Care Products 
(Last modified October 2008) 
Chronic wounds most commonly include pressure ulcers (also called decubitus ulcers or bed sores), diabetic foot ulcers, burns, and varicose ulcers.  They are 
generally difficult to heal and are often resistant to treatment.1  Most pressure ulcers occur in the lower part of the body.  The elderly and bedridden spinal cord 
injury patients are prone to chronic wounds.  Common complications of skin ulcers include osteomyelitis, sepsis, and death.1  Measures to prevent pressure ulcers 
include recognizing patients at risk, reducing bed rest, reducing constant pressure, assessing and maintaining nutritional status, and preserving skin integrity.  
Treatment is based on the extent of the wound.2  Staging of ulcers and other chronic wounds is a common practice and relates to wound depth.  A stage 1 wound is 
identified by nonblanchable redness of intact skin.  Stage 2 is characterized by ulcer extension through the epidermis or dermis.  Stage 3 ulcers extend through the 
full thickness of the skin into the subcutaneous tissue and create a crater.  Stage 4 effects include tissue necrosis with muscle, bone, or underlying structural damage.3  
During the healing process, wounds progress through three, sometimes overlapping, phases:  the inflammatory phase (redness, heat, swelling, pain), the proliferative 
phase (migration of fibroblasts into the wound, cellular proliferation, granulation, angiogenesis), and the maturation phase (new collagen production and deposition, 
migration of epithelial cells).4  Treatment of chronic wounds involves provision of moisture and occlusion, prevention and treatment of infections (several wound 
care lines include products with silver ions for antimicrobial activity), and debridement (the removal of necrotic or fibrous tissue).2,4  Surgical debridement is 
recommended for patients with sepsis or advancing cellulitis.  Autolytic and chemical (enzymatic) debridement take weeks and can be used in less severe cases.4  
Autolytic debridement, which occurs through retention of natural wound fluids, isn’t good for infected or very deep wounds.4  This chart reviews products used for 
the treatment of chronic wounds, including antimicrobials, debriding agents, dressings, and wound cleansers. 




Calcium alginate  
(AlgiDERM, Curasorb [also 
available in Canada], Sorbsan, etc)  
Available as ropes or pads 
• Abrasions/lacerations/skin 
tears 
• Arterial ulcers 
• Deep and tunneling wounds 
• Diabetic ulcers 
• Donor sites 
• Pressure ulcers 
• Second degree burns 













Around $50 for 
a ten-pack of 
dressings [U.S.] 
 
Around $7 per 
dressing 
[Canada] 
• Absorbs wound exudate and forms a gel-like covering 
to facilitate autolytic debridement and maintenance of 
a moist wound environment.5 
• Good for moderately to heavily exudative wounds 
and hemorrhagic wounds.2,5,6 
• Can leave in place until soaked with exudate.2 
• Requires a secondary dressing.5 
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Papain, Urea  
(Accuzyme, EtheZyme, etc) 
Available as foam, ointment, or 
spray 
$54.55 




Chlorophyllin Copper Complex 
(Panafil, Ziox, etc) 
Available as ointment or spray 
• Burn eschar 
• Diabetic foot ulcer 
• Pressure ulcer, stage 2 to 4 
• Varicose ulcer 
 
UPDATE (9/23/08): FDA instructs 
manufacturers to stop marketing 
topical papain-containing products 
due to reports of serious 
hypersensitivity reactions 
associated with their use. Patients 
with latex sensitivity may be at 
increased risk. These products have 
never been approved by the FDA.14 
$88.00 
30 gm tube 
($2.93/gm) 
• Papain is a proteolytic enzyme that debrides necrotic, 
nonviable tissue.4 
• Urea supplements papain by exposing sulfhydryl 
groups in necrotic tissue to papain’s action.4 
• Chlorophyllin copper complex inhibits 
hemagglutination and inflammatory properties of 
protein degradation products.  It promotes healthy 
granulation, reduces inflammation, and reduces odor.4 
• Panafil can be used continuously to promote wound 
healing.7 
• Avoid peroxide or heavy metal (e.g. mercury, silver) 
containing agents as they inactivate papain.4 
• Can be used for infected wounds.4 
Collagenase ointment 
(Santyl) 
• Burn eschar 
• Diabetic foot ulcer 
• Pressure ulcer, stage 2 to 4 
• Varicose ulcer 
$74.24 
30 gm tube 
($2.47/gm) 
• Collagenase is specific for digestion of collagen in 
necrotic tissue.4 
• Can be used for infected wounds.4 
• Optimal pH for enzymatic action is 6 to 8; avoid 
acidic agents for cleansing. 
• Peroxide does not affect its efficacy, but avoid 
detergents and heavy metal (e.g. mercury, silver) 
containing agents.4 
• The only debriding agent covered by Medicare. 
Trypsin, Castor Oil,  
Peru Balsam 
(Granulex, Xenaderm)  
Available as gel, ointment, or 
spray 
• Burn eschar 
• Pressure ulcer, stage 1 to 4 
• Varicose ulcer 
 
$19.41 




30 gm tube 
($2.06/gm) 
• Trypsin is a mild debriding agent. 
• Castor oil and Peru Balsam are protectants.  Peru 
Balsam reduces wound odor. 
• Can be used for infected wounds.4 
• May not be better than mechanical gauze 
debridement.1,8 
• Avoid concurrent use of silver-containing agents 
because they can reduce efficacy. 
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Hydrophilic polyurethane foam 
(Biopatch, Curafoam, Flexzan, etc)  
• Absorptive secondary 
dressing for packed wounds 
• Diabetic ulcers, pressure 
ulcers, and venous stasis 
ulcers 
• Donor sites 
• Draining surgical incisions 
• Granulation tissue 
• Superficial burns 






and $70 for a 
ten-pack of 
dressings 
• Moderately to highly absorbent, semi-occlusive 
dressing. Maintains a moist wound environment and 
absorbs exudate.2,5 
• Good for chronic wounds that are granulating.6  Good 
for cavitating wounds.5 
• Some require a secondary dressing.  Some may be 
used as a secondary dressing.5 
• Change dressing every three to four days.2,5 
• May promote development of malodorous drainage.2 
Hydrocolloids and Hydrogels 
Carboxymethylcellulose 
dressings, granules, patches, and 
paste 
(Aquacel, Curaderm, DuoDerm 













(Curasol, Carrasyn [also available 
in Canada], Nu-Gel, Tegaderm 
[also available in Canada], etc) 
Also available as sheets  
(Flexderm, Vigilon, FlexiGel, etc) 
and gauze (Biolex, Curafil, etc) 
• Cuts and abrasions 
• First and second degree 
burns 
• Pressure ulcers 
• Stasis ulcers 
$18.62 for  





size of dressing 
 
$5 to $10 per 
dressing 
 




• Used to keep a wound moist and absorb exudate, 
while autolytically debriding the wound.5 
• Not for wounds that are producing moderate to heavy 
exudate.  Not for infected wounds.5 
• Hydrocolloids and hydrogels may provide pain 
relief.2 
• These products must be covered by a secondary 
dressing.5 
• Hydrocolloids can develop a foul odor after two to 
four days, which can be mistaken for infection.2,6 
• Hydrocolloids are good for chronic wounds that are 
epithelializing.6  They are considered semi-occlusive 
moisture retentive dressings and can be left in place 
for up to seven days or until fluid leaks.2 
• Hydrogels are good for chronic wounds that are 
debriding.6  They are good for keeping a dry wound 
moist.5  Hydrogels can be left in place for one to three 
days.2 
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(Aquacel, Aquacel AG) 
• Burns 
• Diabetic foot ulcers 
• Donor sites 
• Infected wounds 
• Leg ulcers 
• Pressure ulcers  
• Surgical wounds 
Around $5.00 




• Exudate absorber.  Good for wounds with heavy 
exudate.  Good for mild hemostasis.4,5 
• Can be left in place until soaked with exudate.2 
• Needs to be held in place by a secondary dressing.5 
Iodine Compounds 
Cadexomer Iodine  
Available as a gel (Iodosorb) 
or as a dressing, ointment, or 
powder (Iodoflex [also available in 
Canada]) 
• Chronic nonhealing, 
exuding wounds such as 
pressure or leg ulcers and 
exuding, infected wounds 
$101.60 








Around $8 per 
5”x5” dressing 
• Absorbs exudate and debris, releases iodine for 
antimicrobial activity.2 
• Change the dressing when it turns white, showing that 
the iodine has been depleted.9 
• Requires use of a secondary dressing.9 
• Contraindicated in patients with iodine sensitivity, 
Hashimoto’s thyroiditis, nontoxic nodular goiter, and 
in children.9 
• Potential risk of interaction with systemic lithium.9 
Moisture Vapor Permeable Films 
Bioclusive, CarraFilm, Tegaderm 
HP, etc. 
• Autolytic debridement 
facilitated by the moist 
wound healing environment 
• Clean, closed surgical 
incisions 
• Skin graft donor sites 
• Stage 1 or 2 pressure ulcers 










• Waterproof, but semi-permeable to passage of oxygen 
and water vapor to and from the wound.5 
• Nonabsorbant.2 
• Prevents wound desiccation and contamination by 
bacteria.5 
• Promotes autolysis of necrotic tissue in the wound, 
maintains a moist environment, helps retain growth 
factors in the wound bed.5 
• Good secondary dressings to hold a primary dressing 
in place.  Can also be used as primary dressing.2,5 
• Leave on for up to seven days or until fluid leaks.2 
• May provide pain relief.2 
• Reserve for wounds with minimal exudate.2 
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Becaplermin gel, rh-PDGF 
(Regranex)  
• Diabetic foot ulcer 
(extending into the 




15 gm tube 
($48.33/gm) 
• Becaplermin is a recombinant formulation of platelet-
derived growth factor (rh-PDGF) which promotes cell 
mitogenesis and protein synthesis for granulation 
tissue formulation.2 
• Adequate blood supply to the affected area and the 
absence of necrotic tissue are needed for efficacy.2 
• Repeated use of Regranex (3 or more tubes) may 
increase the risk of cancer-related death.  Use with 
caution in patients with known malignancy.10 
Phenytoin 
(Dilantin, generics [also available 
in Canada])  
Prepared as a suspension of the 
contents of a 100 mg capsule 
mixed with 5 mL sterile saline or 
powder applied directly to wound 
• Burn eschar*** 
• Diabetic foot ulcer*** 
• Pressure ulcer, stage 2*** 










• Phenytoin may stimulate proliferation of fibroblasts, 
enhance granulation tissue, decrease wound exudate, 
promote collagen deposition, and decrease bacterial 
contamination.11,13 
• Topical phenytoin appears to be effective and safe for 
healing soft tissue wounds.11-13 [Evidence level A; 
quantitative systematic review]13 
Topical Antibiotics 
Bacitracin, Neomycin, 
Polymyxin B  
(Neosporin, generics [also 
available in Canada]) 
Available as ointment or cream 
 
$6.36 
30 gm tube 
(generic) 
($0.21/gm) 
Bacitracin, Polymyxin B 
(Polysporin, generics)  







• Prevention or treatment of 
superficial infection 
$6.78 





15 gm tube 
($0.36/gm) 
[Canada] 
• Ointment dosage forms are difficult to remove. 
• May have cytotoxic effects that could delay wound 
healing. 
• Allergic reactions may occur. 
• Bacteria may become resistant with prolonged use. 
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Agent General Indications* Cost of Selected 
Products** 
Comments 
Topical Antibiotics, continued 
Gentamicin  
(Garamycin, generics [also 
available in Canada]) 
Available as ointment or cream 
 
• Prevention or treatment of 
superficial skin and soft 

















• Ointment dosage forms are difficult to remove. 
• May have cytotoxic effects that could delay wound 
healing. 
• Allergic reactions may occur. 
• Bacteria may become resistant with prolonged use. 
Silver sulfadiazine cream 
(Silvadene, SSD, Dermazin 
[Canada]) 
• Prevention of infection in 
second- and third-degree 
burns 
• Prevention or treatment of 
infection in chronic 
wounds*** 
$14.68 










• May have cytotoxic effects that could delay wound 
healing. 
• Allergic reactions may occur. 
• Bacteria may become resistant with prolonged use. 
• Do not use with collagenase, papain, or trypsin-
containing enzymatic debriding agents.4 
Wound Cleansers 
Sterile saline 
(Normal saline for irrigation 0.9%) 








• Best for general wound cleaning and rinsing. 
• Note: avoid other wound cleaners such as povidone 
iodine (Betadine), chlorhexidine gluconate 
(Hibiclens), hypochlorite solution (Dakin’s solution), 
benzalkonium chloride solution, acetic acid solution. 
They can disturb granulation tissue and be cytotoxic 
if not diluted or used too vigorously.1 
• Hydrogen peroxide 3% solution may delay healing 
but 20% solution acts as a healing enhancer.1 
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Agent General Indications* Cost of Selected 
Products** 
Comments 
Wound Cleansers, continued 
Water, surfactant, salt solutions 
(Allclenz, Biolex, Dermagran [also 
available in Canada], UltraKlenz, 
etc) 




• Some contain moisturizing agents.5 
* Information is from U.S. product labeling. 
** Cost information is approximate as of the time this chart was prepared. It is based on average wholesale price (AWP).  Actual selling prices may 
differ. 






Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our editors have researched the information with input from experts, government agencies, and national 










Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based clinical 
review article.  Am Fam Physician 2002;65:251-8. 
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